Paclitaxel for AIDS-associated Kaposi's sarcoma.
Treatment options are limited for patients with advanced acquired immunodeficiency syndrome-related Kaposi's sarcoma (AIDS-KS). The management of early stage cutaneous AIDS-KS has been revolutionized by the introduction of highly active antiretroviral therapy and for most patients highly active antiretroviral therapy alone will control early stage AIDS-KS. However, patients with advanced stage Kaposi's sarcoma with visceral disease, tumor-associated edema or extensive oral disease require systemic chemotherapy in addition to antiretrovirals. The standard first-line therapy for these affected individuals is a liposomal anthracycline, and response rates of around 70% are usually achieved. For patients with refractory or recurrent AIDS-KS, treatment algorithms are less well defined. The use of paclitaxel in these circumstances is reviewed.
Dhillon
Tony
T
Department of Oncology, The Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK.
Stebbing
Justin
J
Bower
Mark
M
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000465:Algorithms; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D006566:Herpesviridae Infections / Q000150:complications; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000627:therapeutic use*; D011379:Prognosis; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000821:virology*
D044966:Anti-Retroviral Agents; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel